Reducing the Risk of PML During MS Treatment
Regular screening for PML is recommended for patients treated with natalizumab.
Neurology Reviews. 2018 July;26(7):58
June 29, 2018|Neurology Reviews
—Randy Dotinga
Suggested Reading
Berger JR. Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord. 2017;12:59-63.
Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology. 2009;72(5):402-409.
Landi D, De Rossi N, Zagaglia S, et al. No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. Neurology. 2017;88(12)
